“Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s730, https://doi.org/10.25251/7mx6d484.